Article

The in vitro elution of gentamicin sulfate from a commercially available gentamicin-loaded acrylic bone cement, VersaBond (TM) AB

Department of Mechanical Engineering, The University of Memphis, Memphis, Tennessee, United States
Journal of Biomedical Materials Research Part B Applied Biomaterials (Impact Factor: 2.33). 10/2004; 71(1):77-83. DOI: 10.1002/jbm.b.30069
Source: PubMed

ABSTRACT The present study was designed to yield results that would be used to contribute to the ongoing debate about the mechanism of the in vitro elution of an antibiotic from an antibiotic-loaded acrylic bone cement. To this end, the elution rates (R) of gentamicin sulfate (expressed as a weight percentage of the initial mass of the antibiotic in the specimen, normalized with respect to the duration of the test) from statically loaded (STATIC) and dynamically loaded (+/-10 MPa; 2 Hz; until fracture; DYNAMIC) specimens fabricated from a commercially available acrylic bone cement (VersaBond AB), in phosphate-buffered saline solution at 37 degrees C, were obtained with the use of a spectrophotometric method. There was evidence of microcracking in the fracture surfaces of DYNAMIC specimens, but no such evidence in the case of STATIC specimens. The surface area of the DYNAMIC specimens, during the tensile phase of the cyclical loading, was estimated to be about 3% larger than for the STATIC specimens (1742 mm(2) versus 1696 mm(2)). The bulk porosities P of the specimens in both sets were also determined and found to not be statistically different, with P for the STATIC and DYNAMIC specimens being 8.55 +/- 0.10 and 8.88 +/- 0.18%, respectively. At the end of the test period, R was found to be 0.36 +/- 0.20 and 1.28 +/- 0.14 wt %/day for the STATIC and DYNAMIC specimens, respectively. It is suggested that the present results provide support for the postulate that the elution mechanism of gentamicin in this cement is a surface phenomenon.

0 Followers
 · 
66 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This work investigates the effect of adding gentamicin, an antibiotic, on the fracture properties of bone cement.Endurance limit, fatigue crack propagation and fracture toughness were determined for a polymethylmethacrylate-based cement, containing 10% w/w of barium sulphate as radiopacifying agent, and the same formulation modified by the addition of 4.22% w/w of gentamicin sulphate.The antibiotic does not affect the endurance limit nor the fracture toughness of the material. There are significant differences in the parameters of the Paris' law fitting the crack growth data: once the main crack is nucleated, it initially propagates at a lower rate but thereafter accelerates faster in gentamicin loaded bone cement. Despite this difference, the growth rate for the same stress intensity factor remains of the same order of magnitude in both formulations.The addition of 4.22% w/w of gentamicin sulphate to radiopaque bone cement has a negligible total effect on the fracture properties of the material.
    Fatigue & Fracture of Engineering Materials & Structures 06/2007; 30(6):479 - 488. DOI:10.1111/j.1460-2695.2007.01109.x · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Bone healing is a complex cascade of events that involves the proliferation and differentiation of osteoblastic cells under the influence of signals from growth factors, cytokines and mechanical loading. Several medications have been found to interact negatively with this process including cytostatics, NSAIDs and corticosteroids; however, the effect of antibiotics on bone repair processes remains obscure. AREAS COVERED: The authors offer a comprehensive review of the existing literature on the in vivo and in vitro effect of antibiotics on bone, bone cells and fracture healing. The authors describe the pharmacokinetic characteristics of antibiotics after parenteral administration as well as their levels when applied locally together with a delivery vehicle. EXPERT OPINION: The available experimental data and clinical evidence are rather limited to allow safe conclusions. In vitro studies indicate that high doses administered after systemic administration have little or no direct effect on bone cells. Further studies are desirable to define the effect of higher or prolonged concentrations on bone biology and especially that of high concentrations released by locally implanted antibiotic-delivery systems, that is, bone cement, spacers and beads.
    Expert Opinion on Drug Safety 08/2011; 10(6):935-45. DOI:10.1517/14740338.2011.589833 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gentamicin is an aminoglycoside antibiotic produced by various species of the genus Micromonospora and has received much attention in the recent years as a broad-spectrum antibiotic for treatment of various infections. It exists as a complex of closely related aminoglycoside structures and the clinically significant one is the gentamicin C complex. This review article focuses attention on the present status of knowledge and the main advancements achieved in the last few decades on the subject of gentamicin with regard to its production, biosynthetic pathway, mode of action, and uses. The various nutritional and environmental parameters affecting gentamicin production and the factors affecting the release of bound gentamicin are discussed. Further, strain improvement using UV and/or chemical mutagenesis can be applied to augment the efficiency of the producer strain and a number of case studies are presented. Different detection and quantitative methods for gentamicin estimation and the mode of action of gentamicin are discussed in detail. This antibiotic finds extensive use in combination chemotherapy and as a drug for different delivery agents for treatment of osteomyelitis and other recent applications in gene therapy.
    Critical Reviews in Biotechnology 02/2008; 28(3):173-212. DOI:10.1080/07388550802262197 · 7.84 Impact Factor